Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies. 

    We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

     

    Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Currently, we do not have any studies available for those diagnosed with liver impairment. We hope to start a study in the near future. 

    Contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1710 Part 1: Individuals with Moderate Renal Impairment

    Research Purpose: To determine whether the investigational drug displays the clinical safety profile to support further development in patients with moderately impaired renal function.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential are allowed to participate

    Age

    40-85 years of age

    Body Mass Index (BMI)

    Between 18-40 kg/m²

    Minimum Weight

    50 kg

    MDRD

    30-59 mL/min/1.73 m²

    Angiotensin receptor blocker (ARB)

    Must be on an ARB for at last a month prior to screening

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 11 weeks. 

    Clinic Stay

    • Participants will be confined at Prism Clinical Research one time during the study period for up to 16 days and (15 nights).

    Return Clinic Visits

    • There is one return clinic visit approximately 1 week after discharge.

     

    Phone Call

    • There is one Phone call approximately 30 days after your final return visit.

     

    Screenings begin: July 19th 2017

    Anticipated start date for Study 1710:  25 July 2017            

     

    Compensation for participation time: Up to $3725.00 if all clinic visits are completed.

                           

    For information regarding this study contact Kevin @: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

  • Study 1708: Male and Female Participants with Migraine

    Research Purpose: Study 1708 is designed to evaluate the cognitive effects in participants receiving topiramate for prophylactic treatment of migraine comparing immediate release versus extended release formulations. Participants will receive dosings of both FDA approved formulations of topiramate.

     The following will be evaluated:

    • The effect of multiple doses of topiramate (immediate release and extended release) on cognition in participants with migraine.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Women using acceptable forms of birth control are allowed to participate.

    Age

    18-65 years

    Body Mass Index (BMI)

    There is no body mass index requirement for this study.

    Weight

    There is no weight requirement for this study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Health History

    History of episodic migraine with or without aura for at least 6 months prior to the screening visit and a frequency of 3 or more headache attacks per month during the past 3 months.

    Right hand dominant.

    On a stable dose for 3 months of a selective serotonin reuptake inhibitor for depression and/or anxiety.

    Special Requirements

    • Must be able and willing to take oral doses of the study medication at home.
    • Must have a working phone number during the entire study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research 3 times
    • The inpatient stay is approximately 1 day one time (1 overnight) and 2 days two times  (2 overnights)

    Outpatient Visits

    • There are 3 outpatient visits during the study.
    • The outpatient visits are approximately 2 hours long. 

     

    Compensation for participation time:   Up to $­­­­­­­­­­­­­­1,660.00

    First screen: 8/28

    First Admit; 9/11

    For information regarding this study contact Kevin at 651-724-5046

  • Study 1712: Healthy Males and Females

    Study 1712 Healthy Female and Male Participants

     

     

    Research Purpose: To evaluate how one drug interacts with an investigational drug being developed for the treatment of high cholesterol.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women on hormonal birth control are allowed to participate provided they use an approved secondary method of birth control.

    Age

    18-60 years of age

    Weight/Body Mass Index (BMI)

    Minimum weight of 50 kg/110 lbs.

    BMI between 18-35 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes within 3 months prior to Check-in.  No tobacco/nicotine use is permitted for the duration of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within  3 months  before the check-in and negative drug screen at screening and Check-in.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 6 weeks.

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in clinic stay will last approximately 17 days (16 overnights)

    Outpatient Visits

    • There are no clinic visits following the discharge from the clinic.

     

    Compensation for participation time: Up to $4,000.00

     

    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1714: Healthy Males and Females

    Study 1714 Healthy Female and Male Participants

     

    Research Purpose: To evaluate how one drug interacts with an investigational drug being developed for the treatment of high cholesterol.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate.

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women using an acceptable method of birth control are allowed to participate.

    Age

    18-60 years of age

    Weight/Body Mass Index (BMI)

    Minimum weight of 50 kg/110 lbs.

    BMI between 18-35 kg/m²

    Tobacco/Nicotine Use

    Subject must be a non-smoker and must have not used tobacco/nicotine containing products including electronic cigarettes within 3 months prior to entering the study.  No tobacco/nicotine use is permitted for the duration of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Medications

    No use of any prescription or nonprescription drugs, vitamins, herbal remedies, or dietary supplements within 14 days of entering the study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 7 weeks.

    Clinic Stay

    • Participants will admit to Prism Clinical Research 2 times.
    • The first in clinic stay will last approximately 4 days (3 overnights).
    • The second in clinic stay will last approximately 4 days (3 overnights).

    Return Clinic Visits

    • There are 12 morning return clinic visits.

     

    Compensation for participation time: Up to $2520.00

     

    For information regarding this study contact Lindsay at: 651-368-3360 lindsayd@prismresearchinc.com or Dayna 651-724-5047 or daynas@prismresearchinc.com

     

Prism Clinical Research Located in the University Enterprise Laboratories (UEL) Building 1000 Westgate Drive, Suite 149, St. Paul, MN 55114 Phone: 651-641-2900 Fax: 651-641-2901

Have questions? Send us a message and we’ll get back to you by the next business day.

Thank you for contacting us. We'll get back to you as soon as we can. If you need to reach someone immediatly pleace call us at 651-641-2900.

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel